

CTI BIOPHARMA CORP  
Form 8-K  
November 06, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 6, 2015

CTI BioPharma Corp.

(Exact Name of Registrant as Specified in its Charter)

Washington                      001-12465      91-1533912  
(State or other jurisdiction of      (Commission (I.R.S. Employer

incorporation or organization) File Number) Identification Number)  
3101 Western Avenue, Suite 600

Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

Seattle, Washington 98121

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 6, 2015, Karen Ignagni notified the Board of Directors (the “Board”) of CTI BioPharma Corp. (the “Company”) of her decision to resign from the Board, with such resignation to be effective immediately. The decision of Ms. Ignagni to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms. Ignagni recently has taken on a new professional role, which requires her full attention.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: By: /s/ Louis A. Bianco  
November  
6, 2015

Louis A. Bianco  
Executive Vice President, Finance and Administration